Serial No.: 10/538625 Group Art Unit No.: 1625

## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (Currently amended) A compound according to Formula (1):

In one aspect of the present invention, there is provided a compound of formula (1):

wherein:

R is selected from the group consisting of:

 $C_{2-6}$  alkyl (optionally substituted by alkoxy, halogen, or  $C_{1-3}$  alkylsulfanyl);  $C_{2-6}$  alkenyl (optionally substituted by alkoxy, halogen, or  $C_{1-3}$ -alkylsulfanyl);  $C_{2-6}$  alkynyl (optionally substituted by alkoxy, halogen, or  $C_{1-3}$ -alkylsulfanyl);  $C_{2-6}$  carbocycle (optionally substituted by alkoxy, halogen, or  $C_{1-3}$  alkylsulfanyl); and  $C_{1-2}$  alkylsulfanyl); and  $C_{1-2}$  alkylsulfanyl) and  $C_{1-2}$  alkylsulfanyl) benzofuran, thiophene, benzothiophene, tetrahydrofuran, tetrahydropyran, dioxane, 1,4-benzodioxane or benzo[1,3]dioxole; R2 is optionally substituted by one or more substituent selected from  $C_{1-2}$  alkyl (optionally substituted by one to three F) and  $C_{1-2}$  alkoxy (optionally substituted by one to three F);

R1 is selected from the group consisting of aryl and heteroaryl;

Y represents  $\Theta$ ,  $\text{CH}_2$  or a covalent bond; and

n is an integer from 0 to 2;

or a <u>pharmaceutically acceptable</u> salt, solvate, or physiologically functional derivative thereof.

Serial No.: 10/538625 Group Art Unit No.: 1625

2. (Currently amended) A compound according to claim 1, with the following absolute configuration:

or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.

3. (Currently amended) A compound according to claim 3 selected from the group consisting of:

Quinoline-8-carboxylic acid ((R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[[.]]:

1,2,3,4-Tetrahydro-quinoline-8-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[[.]]:

Benzofuran-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[[.]]:

Quinoline-6-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[[.]];

- 1,2,3,4-Tetrahydro-quinoline-6-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[[.]];
- 2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoyl]amino}-methyl)-amide[[.]];

7-Methoxy-benzofuran-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[[.]];

5-Methoxy-benzofuran-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[[.]];

Serial No.: 10/538625 Group Art Unit No.: 1625

- 3,4-Dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylic acid ({(R)-2-[(formyl-hydroxyamino)-methyl]-heptanoylamino}-methyl)-amide[[.]];
- 5-Trifluoromethyl-furan-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[[.]]:
- 3,4-Difluoro-N-({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-benzamide[[.]]:
- 2,3-Difluoro-N-({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-benzamide.
- [1,8]Naphthyridine-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[[.]];
- 3-Methyl-benzofuran-2-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[[.]];

Benzo[1,3]dioxole-5-carboxylic acid ({(R)-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide[[.]];

Benzofuran-2-carboxylic acid {[(R)-2-cyclopentylmethyl-3-(formyl-hydroxy-amino)-propanoylamino]-methyl}-amide[[.]]; and

Benzofuran-2-carboxylic acid ({(R)-7,7,7-trifluoro-2-[(formyl-hydroxy-amino)-methyl]-heptanoylamino}-methyl)-amide; or a pharmaceutically acceptable salt thereof.

- 4. (Canceled)
- 5. (New) A pharmaceutical composition comprising a compound according claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- 6. (New) A pharmaceutical composition comprising a compound according claim 3 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.